Related Experiment Videos
S100 in mild traumatic brain injury
Catharina Nygren De Boussard1, Pam Fredman, Anders Lundin
1Department of Rehabilitation Medicine, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden. catharina.nygren@reh.ds.sll.se
Brain Injury
|June 19, 2004
Summary
The diagnostic value of S100 proteins for mild traumatic brain injury (MTBI) was not confirmed. S100A1B shows potential for long-term prognosis in MTBI patients.
Area of Science:
- Biomarkers in Traumatology
- Neurotrauma Research
- Diagnostic Accuracy Studies
Background:
- Mild traumatic brain injury (MTBI) presents diagnostic challenges.
- S100 proteins are potential biomarkers for brain injury.
- Accurate diagnosis is crucial for appropriate patient management.
Purpose of the Study:
- To evaluate the diagnostic utility of S100B, S100A1B, and S100BB in patients with MTBI.
- To compare S100 protein levels in MTBI patients versus orthopedic injury patients and healthy controls.
Main Methods:
- Prospective cohort study design.
- Serum concentrations of S100B, S100A1B, and S100BB were measured.
- Inclusion criteria: MTBI patients (GCS 15 or 14), orthopedic injury patients, and non-injured controls.
Main Results:
- S100B and S100A1B levels were elevated in trauma groups compared to controls.
- S100A1B showed higher sensitivity (61%) and specificity (77%) for MTBI versus orthopedic injury.
- Receiver Operating Characteristic (ROC) curve analysis did not indicate strong diagnostic performance (AUC < 0.9).
Conclusions:
- S100 proteins, including S100A1B, do not demonstrate sufficient diagnostic validity for acute MTBI.
- S100A1B may hold promise for future long-term prognostic studies in MTBI.